Navigation Links
Morphotek(R), Inc. Announces a Licensing Deal With Centocor Ortho Biotech Inc. for Exclusive Development and Commercialization Rights for a Therapeutic Monoclonal Antibody

EXTON, Pa., Oct. 28 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into a license agreement with Centocor Ortho Biotech Inc. for development and commercialization of an antibody that targets a tumor-associated antigen over-expressed in many solid tumors.

Under the terms of the agreement, Morphotek has been granted an exclusive worldwide license for the development, manufacture and sale of the antibody. Financial terms were not disclosed. Preclinical studies, conducted by Centocor Ortho Biotech, have shown that the relevant antigen is over-expressed in many solid tumors.

"We are delighted to conclude this license agreement with Centocor Ortho Biotech as we are committed to bringing healthcare solutions to cancer patients, especially for areas of unmet medical need," said Philip Sass, Ph.D., Chief Operating Officer of Morphotek. "Morphotek is well positioned to apply its technologies, knowledge and expertise in monoclonal antibody development for the development and commercialization of this antibody. The preclinical data package for this antibody have shown anti-cancer effects and we look forward to validating these in human trials."

About Morphotek

Morphotek®, Inc., a subsidiary of Eisai Inc., is a biopharmaceutical company specializing in the development of protein and antibody products through the use of novel and proprietary technologies. The technologies have been successfully applied to a variety of molecules that are suitable for pharmaceutical product development in the areas of antibody therapeutics, protein therapeutics, product manufacturing, drug target discovery, and improved output traits for commercial applications. The company is currently focusing its platform on the development and manufacturing of therapeutic antibodies for the treatment of cancer, inflammation and infectious disease. For more information, please visit

Eisai Inc.

Eisai Inc. is a wholly-owned subsidiary of Eisai Corporation of North America. Established in 1995 and ranked among the top-20 U.S. pharmaceutical companies (based on retail sales), the company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully-integrated pharmaceutical business with fiscal year 2008 (year ended March 31, 2009) sales of approximately $3.7 billion. Eisai Inc.'s areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Headquartered in Woodcliff Lake, New Jersey, Eisai Inc. has several R&D facilities in Massachusetts, New Jersey and North Carolina, as well as manufacturing facilities in Maryland and North Carolina. For more information about Eisai, please visit

*On October 1, 2009, Eisai Research Institute of Boston, Inc. (established in 1987) and Eisai Medical Research Inc. (established in 2002) were merged into Eisai Inc.

SOURCE Morphotek(R), Inc.

SOURCE Morphotek(R), Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Morphotek(R), Inc. Announces FDA Acceptance of Investigational New Drug Application for MORAb-004, a Monoclonal Antibody for the Treatment of Solid Tumors
2. Morphotek(R), Inc. and Eisai Corporation of North America Announce FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian Cancer
3. Connectyx Announces the MedFlash Personal Health Manager
4. Allegheny Medical Announces Launch of the New
5. Zix Corporation Hits High End of Financial Guidance as Company Announces Third Quarter 2009 Financial Results
6. 1-800-Therapist Announces New Executive Team and Tele-Therapy Offering
7. Ziosoft Announces Agreement with Imaging & Medical Information Technology to Distribute Ziosoft's 3D Advanced Visualization Software in Turkey
8. Sorrento Therapeutics Announces the Appointment of Martina Molsbergen as Vice President, Business Development
9. CardioGenics Holdings Inc. Announces Name, Ticker Symbol and CUSIP Number Change
10. Spain-United States Chamber of Commerce Announces 30th Annual Gala Honoring IBT Group at The Biltmore Hotel - November 6
11. Akorn, Inc. Announces Third Quarter 2009 Earnings Release and Conference Call Information
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... Dr. Todd S. Afferica, a noted general ... of his patients. Dr. Afferica now uses the BIOLASE WaterLase iPlus 2.0™ in many ... the doctor uses other traditional cutting tools, such as the scalpel and high-speed drill, ...
(Date:11/24/2015)... ... November 24, 2015 , ... In an article published November 12th ... which patients are or are not eligible for bariatric surgery. The article explains that ... are more than 100 pounds overweight, or have a BMI of 35 and over ...
(Date:11/24/2015)... ... 2015 , ... It takes only three to five seconds to make a ... first impression be positive and reflects business values. If a client starts with a ... to return. They will also share their thoughts about a business with others, which ...
(Date:11/24/2015)... ... 2015 , ... Cancer patients, survivors, caregivers, family members and ... taping of the next CURE Connections® video series on Saturday, Dec. ... at Georgetown University Hotel & Conference Center in Washington, D.C. , CURE Connections, ...
(Date:11/24/2015)... Danbury, CT (PRWEB) , ... November 24, 2015 , ... ... Network (WCHN) today announced an innovative study designed to yield insights into how to ... potential development of biomarkers for pancreatic cancer from small, non-coding RNA molecules (ncRNA), genetic ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... Nueva York , 24 de noviembre ... fabricante del Avery Breathing Pacemaker System, se complace ... MD; Ph.D. como consultor clínico. ... --> Foto -   ... doctor Jonzon es un fisiólogo y consultor en ...
(Date:11/24/2015)... 24, 2015 Avery Biomedical Devices (ABD), manufacturer ... announce the appointment of Anders Jonzon , MD; ... Dr. Jonzon is a Physiologist ... Hospital, Uppsala University, Uppsala and Children,s Hospital, Karolinska, ... a fellow at the Cardiovascular Institute (UCSF). His research ...
(Date:11/24/2015)... November 24, 2015 F1000Workspace - ... - since it was launched just six months ago. ... and authoring platform for scientists - since it was launched ... have been loaded on to F1000Workspace - a ... since it was launched just six months ago. ...
Breaking Medicine Technology: